1
Clinical Trials associated with pGM169-GL67A gene therapy(The National Heart & Lung Institute)Evaluation of Safety and Gene Expression With a Single Dose of pGM169/GL67A Administered to the Nose and Lung of Individuals With Cystic Fibrosis
The study objectives are to assess safety, tolerability and gene expression after a single dose of non-viral CFTR gene therapy (pGM169/GL67A) administered to the nose and lungs of patients with cystic fibrosis.
100 Clinical Results associated with pGM169-GL67A gene therapy(The National Heart & Lung Institute)
100 Translational Medicine associated with pGM169-GL67A gene therapy(The National Heart & Lung Institute)
100 Patents (Medical) associated with pGM169-GL67A gene therapy(The National Heart & Lung Institute)
100 Deals associated with pGM169-GL67A gene therapy(The National Heart & Lung Institute)